Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rotavirus Infections | 38 | 2025 | 353 | 6.850 |
Why?
|
| Caliciviridae Infections | 27 | 2025 | 323 | 5.560 |
Why?
|
| Gastroenteritis | 33 | 2025 | 341 | 5.420 |
Why?
|
| Rotavirus | 35 | 2024 | 497 | 4.650 |
Why?
|
| Norovirus | 28 | 2025 | 312 | 4.410 |
Why?
|
| Organoids | 16 | 2025 | 276 | 3.640 |
Why?
|
| Intestinal Mucosa | 10 | 2025 | 774 | 2.110 |
Why?
|
| Oligosaccharides | 4 | 2025 | 76 | 1.980 |
Why?
|
| Milk, Human | 7 | 2025 | 300 | 1.950 |
Why?
|
| Blood Group Antigens | 8 | 2025 | 73 | 1.680 |
Why?
|
| Polysaccharides | 9 | 2021 | 143 | 1.660 |
Why?
|
| Virus Replication | 13 | 2025 | 604 | 1.580 |
Why?
|
| Rotavirus Vaccines | 9 | 2025 | 71 | 1.570 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2024 | 680 | 1.550 |
Why?
|
| Antibodies, Viral | 13 | 2024 | 1133 | 1.480 |
Why?
|
| Viral Vaccines | 7 | 2024 | 325 | 1.400 |
Why?
|
| Cell Culture Techniques | 6 | 2021 | 287 | 1.280 |
Why?
|
| Viruses | 5 | 2023 | 123 | 1.210 |
Why?
|
| Capsid Proteins | 10 | 2014 | 181 | 1.130 |
Why?
|
| Immunoglobulin A | 6 | 2016 | 197 | 1.080 |
Why?
|
| Vaccines, Virus-Like Particle | 3 | 2024 | 34 | 1.050 |
Why?
|
| India | 26 | 2021 | 217 | 1.020 |
Why?
|
| Trisaccharides | 1 | 2025 | 6 | 0.970 |
Why?
|
| Diarrhea | 12 | 2018 | 315 | 0.960 |
Why?
|
| Intestines | 8 | 2024 | 571 | 0.920 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 62 | 0.920 |
Why?
|
| Epithelial Cells | 5 | 2021 | 901 | 0.890 |
Why?
|
| Genotype | 21 | 2024 | 2548 | 0.880 |
Why?
|
| Feces | 19 | 2024 | 710 | 0.800 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2018 | 171 | 0.750 |
Why?
|
| Virus Physiological Phenomena | 2 | 2018 | 14 | 0.750 |
Why?
|
| Antigens, Viral | 9 | 2020 | 436 | 0.730 |
Why?
|
| Infant, Newborn | 25 | 2024 | 8089 | 0.720 |
Why?
|
| Stem Cells | 6 | 2021 | 701 | 0.710 |
Why?
|
| Viral Proteins | 6 | 2021 | 348 | 0.680 |
Why?
|
| Antiviral Agents | 5 | 2025 | 740 | 0.660 |
Why?
|
| Humans | 84 | 2025 | 123180 | 0.640 |
Why?
|
| Nurseries, Hospital | 2 | 2008 | 6 | 0.630 |
Why?
|
| Enterovirus | 1 | 2019 | 48 | 0.620 |
Why?
|
| Enterovirus Infections | 1 | 2019 | 42 | 0.620 |
Why?
|
| Viral Nonstructural Proteins | 6 | 2018 | 193 | 0.620 |
Why?
|
| Norwalk virus | 3 | 2024 | 170 | 0.600 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 298 | 0.590 |
Why?
|
| RNA, Viral | 7 | 2012 | 540 | 0.560 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 14 | 0.550 |
Why?
|
| Milk | 1 | 2017 | 118 | 0.530 |
Why?
|
| Virus Diseases | 2 | 2021 | 280 | 0.530 |
Why?
|
| Immunoglobulin G | 6 | 2019 | 771 | 0.500 |
Why?
|
| Host-Pathogen Interactions | 5 | 2021 | 251 | 0.500 |
Why?
|
| Receptors, Virus | 5 | 2018 | 104 | 0.500 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 518 | 0.490 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 459 | 0.490 |
Why?
|
| RNA-Binding Proteins | 3 | 2018 | 573 | 0.460 |
Why?
|
| Reassortant Viruses | 2 | 2015 | 34 | 0.450 |
Why?
|
| Infant | 21 | 2024 | 12323 | 0.410 |
Why?
|
| Hospitalization | 7 | 2024 | 1733 | 0.400 |
Why?
|
| Viral Load | 2 | 2010 | 382 | 0.390 |
Why?
|
| Virus Shedding | 2 | 2013 | 79 | 0.380 |
Why?
|
| Asymptomatic Infections | 1 | 2010 | 33 | 0.360 |
Why?
|
| Virus Cultivation | 3 | 2024 | 76 | 0.350 |
Why?
|
| Viremia | 1 | 2010 | 126 | 0.350 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2020 | 1294 | 0.340 |
Why?
|
| Transcriptome | 4 | 2024 | 909 | 0.330 |
Why?
|
| Cost of Illness | 2 | 2009 | 242 | 0.320 |
Why?
|
| Infant, Premature | 3 | 2024 | 798 | 0.320 |
Why?
|
| Diarrhea, Infantile | 1 | 2008 | 36 | 0.310 |
Why?
|
| Genome, Viral | 1 | 2009 | 171 | 0.310 |
Why?
|
| Intestine, Small | 2 | 2021 | 302 | 0.310 |
Why?
|
| Cross Infection | 2 | 2008 | 332 | 0.290 |
Why?
|
| Culture Media | 3 | 2024 | 182 | 0.290 |
Why?
|
| Protease Inhibitors | 2 | 2025 | 95 | 0.280 |
Why?
|
| Poverty Areas | 1 | 2006 | 31 | 0.280 |
Why?
|
| Geographic Information Systems | 1 | 2006 | 40 | 0.280 |
Why?
|
| Gastrointestinal Tract | 3 | 2021 | 208 | 0.270 |
Why?
|
| Animals | 18 | 2024 | 33728 | 0.270 |
Why?
|
| Mothers | 2 | 2013 | 350 | 0.270 |
Why?
|
| Gastrointestinal Diseases | 2 | 2021 | 335 | 0.260 |
Why?
|
| Adult | 13 | 2025 | 29039 | 0.260 |
Why?
|
| Infant, Premature, Diseases | 1 | 2008 | 238 | 0.260 |
Why?
|
| Enterocytes | 2 | 2024 | 71 | 0.260 |
Why?
|
| Cricetulus | 2 | 2018 | 101 | 0.260 |
Why?
|
| CHO Cells | 2 | 2018 | 159 | 0.260 |
Why?
|
| Fucosyltransferases | 3 | 2021 | 29 | 0.250 |
Why?
|
| Urban Population | 1 | 2006 | 221 | 0.250 |
Why?
|
| Cricetinae | 2 | 2018 | 410 | 0.250 |
Why?
|
| Phylogeny | 4 | 2014 | 685 | 0.250 |
Why?
|
| Drug Discovery | 2 | 2023 | 171 | 0.230 |
Why?
|
| Cryptosporidium | 2 | 2020 | 32 | 0.230 |
Why?
|
| Species Specificity | 5 | 2017 | 549 | 0.230 |
Why?
|
| Antibodies, Blocking | 2 | 2024 | 61 | 0.230 |
Why?
|
| Poliovirus Vaccine, Oral | 2 | 2025 | 4 | 0.230 |
Why?
|
| Lentivirus | 1 | 2024 | 84 | 0.230 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2024 | 93 | 0.220 |
Why?
|
| Jejunum | 1 | 2024 | 128 | 0.220 |
Why?
|
| Child, Preschool | 16 | 2024 | 13862 | 0.220 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 752 | 0.220 |
Why?
|
| Cattle | 4 | 2015 | 559 | 0.220 |
Why?
|
| Vaccination | 4 | 2025 | 949 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 1 | 2024 | 350 | 0.210 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2024 | 168 | 0.200 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 665 | 0.200 |
Why?
|
| Cell Survival | 1 | 2024 | 803 | 0.200 |
Why?
|
| Virus Attachment | 3 | 2021 | 41 | 0.190 |
Why?
|
| Blotting, Western | 1 | 2024 | 1102 | 0.190 |
Why?
|
| Flow Cytometry | 1 | 2024 | 803 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2024 | 372 | 0.190 |
Why?
|
| Acute Disease | 4 | 2024 | 1090 | 0.190 |
Why?
|
| Male | 21 | 2024 | 60022 | 0.190 |
Why?
|
| Female | 20 | 2024 | 65428 | 0.180 |
Why?
|
| Cell Line | 4 | 2020 | 2776 | 0.180 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 141 | 0.180 |
Why?
|
| Interferons | 1 | 2020 | 120 | 0.170 |
Why?
|
| Ceramides | 1 | 2020 | 38 | 0.170 |
Why?
|
| Virus Internalization | 1 | 2020 | 54 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2021 | 4709 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 2 | 2016 | 120 | 0.160 |
Why?
|
| Colon | 1 | 2021 | 353 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 5 | 2021 | 1586 | 0.160 |
Why?
|
| Interdisciplinary Research | 1 | 2018 | 5 | 0.150 |
Why?
|
| Tissue Culture Techniques | 1 | 2018 | 70 | 0.150 |
Why?
|
| Tissue Engineering | 1 | 2020 | 177 | 0.150 |
Why?
|
| Breast Feeding | 2 | 2018 | 220 | 0.150 |
Why?
|
| Glycomics | 2 | 2014 | 16 | 0.150 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 155 | 0.150 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 234 | 0.150 |
Why?
|
| Protein Binding | 3 | 2021 | 1743 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 423 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 2838 | 0.140 |
Why?
|
| Neutralization Tests | 3 | 2024 | 237 | 0.140 |
Why?
|
| Staining and Labeling | 2 | 2014 | 183 | 0.140 |
Why?
|
| N-Acetylneuraminic Acid | 2 | 2014 | 27 | 0.140 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 192 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1916 | 0.140 |
Why?
|
| Biopsy | 1 | 2020 | 1239 | 0.130 |
Why?
|
| Cattle Diseases | 1 | 2015 | 21 | 0.130 |
Why?
|
| Carbohydrate Sequence | 1 | 2014 | 17 | 0.120 |
Why?
|
| Gene Expression | 1 | 2019 | 1569 | 0.120 |
Why?
|
| Protein Conformation | 3 | 2021 | 836 | 0.120 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 42 | 0.120 |
Why?
|
| Saliva | 1 | 2015 | 113 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 327 | 0.110 |
Why?
|
| Hemagglutination Tests | 1 | 2013 | 11 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1015 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 3871 | 0.110 |
Why?
|
| Models, Molecular | 3 | 2021 | 1070 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 5 | 2010 | 1760 | 0.100 |
Why?
|
| Travel | 1 | 2014 | 117 | 0.100 |
Why?
|
| Binding Sites | 3 | 2021 | 1292 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2025 | 160 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2024 | 3260 | 0.100 |
Why?
|
| Genes, Viral | 2 | 2008 | 183 | 0.090 |
Why?
|
| Prevalence | 5 | 2020 | 2405 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 31 | 0.090 |
Why?
|
| Biodiversity | 1 | 2010 | 64 | 0.090 |
Why?
|
| Bifidobacterium | 1 | 2010 | 63 | 0.090 |
Why?
|
| Sequence Homology | 1 | 2009 | 62 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2020 | 262 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 8870 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 815 | 0.080 |
Why?
|
| Beds | 1 | 2008 | 9 | 0.080 |
Why?
|
| Child | 3 | 2025 | 24208 | 0.080 |
Why?
|
| Community-Acquired Infections | 2 | 2007 | 241 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2019 | 357 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 281 | 0.070 |
Why?
|
| Caliciviridae | 1 | 2007 | 19 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5048 | 0.060 |
Why?
|
| Cryptosporidiosis | 1 | 2006 | 41 | 0.060 |
Why?
|
| Hospitals | 1 | 2008 | 397 | 0.060 |
Why?
|
| Cholera Vaccines | 1 | 2025 | 4 | 0.060 |
Why?
|
| Crystallography | 1 | 2025 | 40 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 138 | 0.060 |
Why?
|
| Poliomyelitis | 1 | 2025 | 17 | 0.060 |
Why?
|
| Seasons | 1 | 2006 | 303 | 0.060 |
Why?
|
| Cholera | 1 | 2025 | 25 | 0.060 |
Why?
|
| Molecular Conformation | 1 | 2025 | 100 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2006 | 383 | 0.060 |
Why?
|
| Proteobacteria | 1 | 2024 | 19 | 0.060 |
Why?
|
| Middle Aged | 5 | 2024 | 25980 | 0.060 |
Why?
|
| Mice | 4 | 2024 | 17486 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2020 | 3049 | 0.050 |
Why?
|
| Food, Fortified | 1 | 2024 | 96 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2024 | 0.050 |
Why?
|
| Biological Assay | 1 | 2023 | 101 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2025 | 671 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 1390 | 0.050 |
Why?
|
| Reference Standards | 1 | 2023 | 241 | 0.050 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2024 | 191 | 0.050 |
Why?
|
| Glycoconjugates | 1 | 2021 | 7 | 0.050 |
Why?
|
| Polyproteins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Laminin | 1 | 2021 | 59 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2021 | 93 | 0.050 |
Why?
|
| Calcitriol | 1 | 2021 | 80 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 137 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 44 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2021 | 271 | 0.040 |
Why?
|
| Zoonoses | 2 | 2013 | 43 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 6028 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 235 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 101 | 0.040 |
Why?
|
| United States | 3 | 2024 | 10618 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 100 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 102 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 231 | 0.040 |
Why?
|
| Time Factors | 1 | 2010 | 6201 | 0.040 |
Why?
|
| Collagen | 1 | 2021 | 313 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2024 | 935 | 0.040 |
Why?
|
| Sporozoites | 1 | 2020 | 2 | 0.040 |
Why?
|
| Oocysts | 1 | 2020 | 3 | 0.040 |
Why?
|
| Glycochenodeoxycholic Acid | 1 | 2020 | 8 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2020 | 63 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 471 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2020 | 42 | 0.040 |
Why?
|
| Adsorption | 1 | 2019 | 32 | 0.040 |
Why?
|
| Haplorhini | 1 | 2019 | 123 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 153 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 131 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 191 | 0.040 |
Why?
|
| Myofibroblasts | 1 | 2020 | 75 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 96 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 114 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2020 | 234 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 74 | 0.040 |
Why?
|
| Chile | 1 | 2018 | 21 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 2018 | 18 | 0.040 |
Why?
|
| Fucose | 1 | 2018 | 21 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2021 | 283 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 199 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 376 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 251 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 3098 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2018 | 293 | 0.040 |
Why?
|
| Toxins, Biological | 2 | 2007 | 70 | 0.040 |
Why?
|
| Bile | 1 | 2016 | 46 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2016 | 34 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2021 | 980 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1695 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1442 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2007 | 369 | 0.030 |
Why?
|
| Kobuvirus | 1 | 2014 | 2 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 1868 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 4267 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 2698 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2014 | 173 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 119 | 0.030 |
Why?
|
| Mexico | 1 | 2014 | 178 | 0.030 |
Why?
|
| Immunoassay | 1 | 2014 | 127 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 168 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 238 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2533 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2014 | 320 | 0.020 |
Why?
|
| Base Sequence | 2 | 2007 | 3093 | 0.020 |
Why?
|
| Denaturing Gradient Gel Electrophoresis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1582 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 54 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1588 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 426 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 661 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 72 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1315 | 0.020 |
Why?
|
| Cats | 1 | 2007 | 117 | 0.020 |
Why?
|
| Sapovirus | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 20 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1420 | 0.020 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2007 | 114 | 0.020 |
Why?
|
| Carrier State | 1 | 2007 | 76 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 365 | 0.020 |
Why?
|
| Dogs | 1 | 2007 | 763 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2006 | 29 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 143 | 0.020 |
Why?
|
| Protozoan Proteins | 1 | 2006 | 109 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 5774 | 0.010 |
Why?
|
| Virulence | 1 | 2004 | 259 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 477 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 19087 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 10000 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 2801 | 0.010 |
Why?
|